郭帅魁,古贤君,黄小杏

系统性红斑狼疮（SLE）是一种典型的自身免疫性疾病，可累及身体多个器官。在疾病过程中，肾脏受累称为狼疮性肾炎（LN），约30%-60%的成年系统性红斑狼疮患者在病程中累及肾脏。因此，肾脏是SLE主要累及的器官之一，也是这些患者发病负担加重和生存率降低的原因。目前，肾活检被认为是对LN进行分类以及确定其活动程度或慢性程度的金标准，但其侵入性强、重复性差，且具有高成本和高风险性，难以动态监测。因此，人们研究很多用于确定LN的常规生物标志物，如蛋白尿、随机尿蛋白/肌酐比值、24小时尿蛋白、肌酐清除率、双链抗DNA水平和血清补体等。但是，以上这些生物标志物可能不足以准确预测复发、精确监测治疗反应，或识别疾病活动程度和慢性损伤程度。此外，非传统生物标志物已与不同类型LN的组织学发现相关。因此，显然需要研究新的潜在生物标志物来克服这些障碍。本综述主要对近几年的一些狼疮肾炎的潜在检测生物标志物的研究进行总结与概括，为LN的监测和治疗提供新的研究方向。

系统性红斑狼疮；狼疮肾炎；肾活检；潜在检测生物标志物

[1] Morimoto A M,Flesher D T,Yang J,et al.Association of endogenous anti-interferon-alpha autoantibodies with decreased interferon- pathway and disease activity in patients with systemic lupus erythematosus[J].Arthritis Rheum,2011,63(8):2407-2415. [2] Levy D M,Kamphuis S.Systemic lupus erythematosus in children and adolescents[J].Pediatr Clin North Am,2012,59(2):345-364. [3] Yap D Y,Tang C S,Ma M K,et al.Survival analysis and causes of mortality in patients with lupus nephritis[J].Nephrol Dial Transplant, 2012,27(8):3248-3254. [4] Pinheiro S V B,Dias R F,Fabiano R C G,et al.Pediatric lupus nephritis[J].Brazilian Journal of Nephrology,2019,41(2):252-265. [5] Aragon C C,Tafur R A,Suarez-Avellaneda A,et al.Urinary biomarkers in lupus nephritis[J].J Transl Autoimmun,2020,3:100042. [6] Weening J J,D'Agati V D,Schwartz M M,et al.The classification of glomerulonephritis in systemic lupus erythematosus revisited[J]. Kidney Int,2004,65(2):521-530. [7] Zickert A,Sundelin B,Svenungsson E,et al.Role of early repeated renal biopsies in lupus nephritis[J].Lupus Sci Med,2014,1(1):e18. [8] Ligtenberg G,Arends S,Stegeman C A,et al.Predictors of renal flares and long-term renal outcome in patients with lupus nephritis:results from daily clinical practice[J].Clin Exp Rheumatol,2022,40(1):33-38. [9] Soliman S,Mohan C.Lupus nephritis biomarkers[J].Clin Immunol,2017,185:10-20. [10] Hartung E A.Biomarkers and surrogate endpoints in kidney disease[J].Pediatr Nephrol,2016,31(3):381-391. [11] Tran L H,Graulus G J,Vincke C,et al.Nanobodies for the Early Detection of Ovarian Cancer[J].Int J Mol Sci,2022,23(22). [12] Zhang R,Siu M,Ngan H,et al.Molecular Biomarkers for the Early Detection of Ovarian Cancer[J].Int J Mol Sci,2022,23(19). [13] LeBleu V S,Teng Y,O'Connell J T,et al.Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis[J].Nat Med,2013,19(2):227-231. [14] Nagy B J,Nagy B,Fila L,et al.Human Epididymis Protein 4:A Novel Serum Inflammatory Biomarker in Cystic Fibrosis[J].Chest,2016, 150(3):661-672. [15] Yang Z,Zhang Z,Qin B,et al.Human Epididymis Protein 4:A Novel Biomarker for Lupus Nephritis and Chronic Kidney Disease in Systemic Lupus Erythematosus[J].Journal of Clinical Laboratory Analysis,2016,30(6):897-904. [16] Ren Y,Xie J,Lin F,et al.Serum human epididymis protein 4 is a predictor for developing nephritis in patients with systemic lupus erythematosus:A prospective cohort study[J].Int Immunopharmacol,2018,60:189-193. [17] Li L,Xu H,Le Y,et al.Elevated serum levels of human epididymis protein 4 in adult patients with proliferative lupus nephritis[J]. Frontiers in Immunology,2023,14. [18] Zhang Z,Kyttaris V C,Tsokos G C.The role of IL-23/IL-17 axis in lupus nephritis[J].J Immunol,2009,183(5):3160-3169. [19] Gaffen S L,Jain R,Garg A V,et al.The IL-23-IL-17 immune axis:from mechanisms to therapeutic testing[J].Nat Rev Immunol, 2014,14(9):585-600. [20] Huang Dedong Z F S J,Shaoyang W.ACCEPTED MANUSCRIPT[J].2019. [21] Karnell J L,Ettinger R.The Interplay of IL-21 and BAFF in the Formation and Maintenance of Human B Cell Memory[J].Front Immunol,2012,3:2. [22] Shater H,Fawzy M,Farid A,et al.The potential use of serum interleukin-21 as biomarker for lupus nephritis activity compared to cytokines of the tumor necrosis factor(TNF)family[J].Lupus,2022,31(1):55-64. [23] Loimaranta V,Hepojoki J,Laaksoaho O,et al.Galectin-3-binding protein:A multitask glycoprotein with innate immunity functions in viral and bacterial infections[J].J Leukoc Biol,2018,104(4):777-786. [24] Nielsen C T,Ostergaard O,Rasmussen N S,et al.A review of studies of the proteomes of circulating microparticles:key roles for galectin-3-binding protein-expressing microparticles in vascular diseases and systemic lupus erythematosus[J].Clin Proteomics,2017,14:11. [25] Rasmussen N S,Nielsen C T,Jacobsen S,et al.Stimulation of Mononuclear Cells Through Toll-Like Receptor 9 Induces Release of Microvesicles Expressing Double-Stranded DNA and Galectin 3-Binding Protein in an Interferon-alpha-Dependent Manner[J].Front Immunol,2019,10:2391. [26] Iacobelli S,Arno E,D'Orazio A,et al.Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer[J].Cancer Res,1986,46(6):3005-3010. [27] Nielsen C T,Lood C,Ostergaard O,et al.Plasma levels of galectin-3-binding protein reflect type I interferon activity and are increased in patients with systemic lupus erythematosus[J].Lupus Sci Med,2014,1(1):e26. [28] Faustini F,Idborg H,Fuzzi E,et al.Urine Galectin-3 binding protein reflects nephritis activity in systemic lupus erythematosus[J]. Lupus,2023,32(2):252-262. [29] Ding H,Shen Y,Lin C,et al.Urinary galectin-3 binding protein(G3BP)as a biomarker for disease activity and renal pathology characteristics in lupus nephritis[J].Arthritis Research&Therapy,2022,24(1). [30] Cowland J B,Borregaard N.Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans[J].Genomics,1997,45(1):17-23. [31] Nielsen B S,Borregaard N,Bundgaard J R,et al.Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases[J].Gut,1996,38(3):414-420. [32] Rubinstein T,Pitashny M,Putterman C.The novel role of neutrophil gelatinase-B associated lipocalin(NGAL)/Lipocalin-2 as a biomarker for lupus nephritis[J].Autoimmun Rev,2008,7(3):229-234. [33] Mishra J,Ma Q,Prada A,et al.Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury[J].J Am Soc Nephrol,2003,14(10):2534-2543. [34] Trachtman H,Christen E,Cnaan A,et al.Urinary neutrophil gelatinase-associated lipocalcin in D+HUS:a novel marker of renal injury[J].Pediatr Nephrol,2006,21(7):989-994. [35] Mishra J,Mori K,Ma Q,et al.Neutrophil gelatinase-associated lipocalin:a novel early urinary biomarker for cisplatin nephrotoxicity[J]. Am J Nephrol,2004,24(3):307-315. [36] Bennett M,Dent C L,Ma Q,et al.Urine NGAL predicts severity of acute kidney injury after cardiac surgery:a prospective study[J].Clin J Am Soc Nephrol,2008,3(3):665-673. [37] Malyszko J,Malyszko J S,Bachorzewska-Gajewska H,et al.Neutrophil gelatinase-associated lipocalin is a new and sensitive marker of kidney function in chronic kidney disease patients and renal allograft recipients[J].Transplant Proc,2009,41(1):158-161. [38] Rubinstein T,Pitashny M,Levine B,et al.Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis[J].Rheumatology,2010,49(5):960-971. [39] Gao Y,Wang B,Cao J,et al.Elevated Urinary Neutrophil Gelatinase‐Associated Lipocalin Is a Biomarker for Lupus Nephritis:A Systematic Review and Meta‐Analysis[J].BioMed Research International,2020,2020(1). [40] RabrenovićV,PetrovićM,RabrenovićM.Comparison urine neutrophil gelatinase-associated lipocalin with standard parameters in monitoring activity Lupus nephritis:Class IV[J].Journal of Medical Biochemistry,2023,42(1):78-85. [41] Ibrahim W H M,Sabry A A,Abdelmoneim A R,et al.Urinary neutrophil gelatinase-associated lipocalin(uNGAL)and kidney injury molecule-1(uKIM-1)as markers of active lupus nephritis[J].Clinical Rheumatology,2024,43(1):167-174. [42] Ribatti D.Endogenous inhibitors of angiogenesis:a historical review[J].Leuk Res,2009,33(5):638-644. [43] Nyberg P,Xie L,Kalluri R.Endogenous inhibitors of angiogenesis[J].Cancer Res,2005,65(10):3967-3979. [44] Wu T,Du Y,Han J,et al.Urinary angiostatin--a novel putative marker of renal pathology chronicity in lupus nephritis[J].Mol Cell Proteomics,2013,12(5):1170-1179. [45] Lakasing L,Campa J S,Parmar K,et al.Normal expression of cell adhesion molecules in placentae from women with systemic lupus erythematosus and the antiphospholipid syndrome[J].Placenta,2000,21(2-3):142-149. [46] Szekanecz Z,Koch A E.Vascular involvement in rheumatic diseases:'vascular rheumatology'[J].Arthritis Res Ther,2008,10(5):224. [47] Soliman S,Mohamed F A,Ismail F M,et al.Urine angiostatin andVCAM‐1 surpass conventional metrics in predicting elevated renal pathology activity indices in lupus nephritis[J].International Journal of Rheumatic Diseases,2017,20(11):1714-1727. [48] Mok C C,Soliman S,Ho L Y,et al.Urinary angiostatin,CXCL4 and VCAM-1 as biomarkers of lupus nephritis[J].Arthritis Research& Therapy,2018,20(1). [49] Nalbandian A,Crispin J C,Tsokos G C.Interleukin-17 and systemic lupus erythematosus:current concepts[J].Clin Exp Immunol, 2009,157(2):209-215. [50] Kwan B C,Tam L S,Lai K B,et al.The gene expression of type 17 T-helper cell-related cytokines in the urinary sediment of patients with systemic lupus erythematosus[J].Rheumatology(Oxford),2009,48(12):1491-1497. [51] Saber N Z,Maroof S H,Soliman D A,et al.Expression of T helper 17 cells and interleukin 17 in lupus nephritis patients[J].The Egyptian Rheumatologist,2017,39(3):151-157. [52] 刘莉,赵春华,闵寒.白细胞介素-6与肠易激综合征:机制与研究进展[J].协和医学杂志,2025:1-14. [53] Su H,Lei C T,Zhang C.Interleukin-6 Signaling Pathway and Its Role in Kidney Disease:An Update[J].Front Immunol,2017,8:405. [54] Tsai C Y,Wu T H,Yu C L,et al.Increased excretions of beta2-microglobulin,IL-6,and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis[J].Nephron,2000,85(3):207-214. [55] 汤可.血清标记物对狼疮肾炎的预测价值分析[J].实用医技杂志,2024,31(09):626-631. [56] So B Y F,Yap D Y H,Chan T M.MicroRNAs in Lupus Nephritis-Role in Disease Pathogenesis and Clinical Applications[J]. International journal of molecular sciences,2021,22(19):10737. [57] Chen F,Shi B,Liu W,et al.Circulating exosomal microRNAs as biomarkers of lupus nephritis[J].Frontiers in Immunology,2023,14. [58] ElFeky D S,Omar N M,Shaker O G,et al.Circulatory microRNAs and proinflammatory cytokines as predictors of lupus nephritis[J]. Frontiers in Immunology,2024,15. [59] Ju W,Nair V,Smith S,et al.Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker[J].Sci Transl Med,2015,7(316):316ra193. [60] Mejia Vilet J M,Shapiro J P,Zhang X L,et al.Association Between Urinary Epidermal Growth Factor and Renal Prognosis in Lupus Nephritis[J].Arthritis&Rheumatology,2021,73(2):244-254. [61] Zhu H,Wan H,Duan S,et al.Value of monitoring urine ammonia at time of biopsy in patients with lupus nephritis[J].BMC Nephrology, 2020,21(1).

点击下载PDF